Archive for 2010 Archive for 2009 Archive for 2008 Archive for 2007 Archive for 2006 Archive for 2005 Archive for 2004 Archive for 2003
Archive for 2002 Archive for 2001 Archive for 2000 Archive for 1999 Archive for 1998 1997 1995-1996  

2006 Archive
(listed in reverse chronological order)

December 17th, 2006

Emerging New Agents in Diabetic Kidney Disease   
Lewis: There are at least five new approaches beyond ACE inibitors to diabetic nephropathy: Aldosterone blockers, ruboxistaurin, prifenidone, COX-2 inhibition, and sulodexide. What is the rationale for each of these interventions and what do the early pilot studies show? (ASN Renal Week 2005).

Coronary Angioplasty and Stenting: Indications and Results   
Williams: In diabetics mortality with CAD is increased and classically they do worse with percutaneous interventions due to restenosis rathen than with bypass surgery. Is this also true for diabetic patients with CKD? To what extent has the picture changed with the use of drug-eluting stents? What are the anti-thrombotic strategies that can be used in such patients after stenting and how do these influence outcomes? (ASN Renal Week 2005).


(Article Free, $CE)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Symptom Occurrence, Symptom Distress, and Quality Of Life in Renal Transplant Recipients
(Vol 33/No. 6. Expires 12/20/2008)
April Zarifian, APRN, DNSc, CNN
1.5 hr

Narrative Literature Review: Sexual Dysfunction in the Patient on Hemodialysis
(Vol 33/No. 6. Expires: 12/20/2008)
Merry Stewart, MSN, RN, APRN
1.4 hr

A Preceptor Training Program Model for the Hemodialysis Setting
(Vol 33/No. 6. Expires: 12/20/2008)
Chris Singer, MN, RN, CNN
1.4 hr

Erythropoietin Claims Monitoring Policy: Implications of the October 2006 Update
(Vol 33/No. 6. Expires: 12/20/2008)
Tony Messana
1.4 hr

Chronic Kidney Disease and Cardiovascular Disease - Using the ANNA Standards and Practice Guidelines to Improve Care
(Vol 33/No. 6. Expires 12/20/2008)
Patricia B. McCarley, MSN, RN, NP, CNN, Sally Burrows-Hudson, MS, RN, CNN
1,4 hr

Annual Dialysis Conference 2006
now in MP3

Update on Vascular Calcification in Chronic Kidney Disease (CKD) Patients
Isaac Teitelbaum, MD; Robert Toto, MD; Dennis Andress, MD; Gerard M. London, MD

What Do We Know About Uremic Toxins?
William R. Clark, MD; Bernard J. Canaud, MD; Thomas A. Depner, MD; Muriel P.C. Grooteman, MD, PhD

Anemia in the PD Patient
Michael V. Rocco, MD, MS, FACP; Allen R. Nissenson, MD, FACP; Chaim Charytan, MD; David B. Van Wyck, MD

Low Bone Turnover Disease: Consequences, Prevalence, Detection and Treatment
Thomas L. Cantor, BA; Hassan Fehmi, MD; Gerard M. London, MD; Simon Waller, MD, MBBS, BSc

November 30th, 2006

Ethylene Glycol Poisoning   
Oh: How is ethylene glycol metabolized, and which metabolites are toxic? What form of calcium oxalate crystals are produced, and is the dihydrate envelope-shaped calcium oxalate crystal frequently seen? Is glycolic acid really the toxic substance in ethylene glycol poisoning, or is it the aldehydes, or the glyoxylic acid? Is metabolism to oxalate or to glycine more important? How does metabolism of ethylene glycol affect acid load? Osmlolal gap? Why might the urinary osmolal gap be of interest? How do we use ethanol and fomepizole in the management of ethylene glycol poisoning? When and for how long do we dialyze? (ASN Renal Week 2005).

Columbia University

Biopsy Conference: A middle-aged male with primary biliary cirrhosis and renal insufficiency.

(Columbia University Nephrology and Pathology Faculty; November, 2006)

A middle-aged male with primary biliary cirrhosis, nephrotic proteinuria, inactive urine sediment, low complement, renal insufficiency. Is it hepatic glomerulopathy, immune complex glomerulonephropathy, or membranous lupus? Teaching points: MGN is the most common glomerular disease in patients with PBC It is extremely rare (<10 cases). IF shows IgG, IgM, C1q. The pathogenesis is in situ immune formation (anti-mitochondrial globulins extracted from the subepithelial deposits? - evidence of common mechanism)
(Edited by Jai Radhakrishnan, MD). (more...)

Annual Dialysis Conference 2006
now in MP3

Explaining and Correcting PD Underutilization
Madhukar Misra, MD; John Burkart, MD; Allen R. Nissenson, MD, FACP; Irum Shahab, MD; Martin Schreiber, MD; Rajnish Mehrotra, MD, MBBS; Dimitrios G. Oreopoulos, MD, PhD, FRCPC, FACP; Martin Schreiber, MD

Emerging Dialysis Techniques
Derrick Latos, MD; Robert S. Lockridge, Jr., MD

Workshop: Non-Infectious Complications of PD
Joanne Bargman, MD, FRCPC

Nursing Home Dialysis: A Primer
Stephen Korbet, MD; Steven Bucher, CPA, MBA

Biocompatible Dialysis
Bengt Lindholm, MD, PhD; Roberto Pecoits-Filho, MD; Bernard J. Canaud, MD; Richard A. Ward, PhD; James F. Winchester, MD

Special Session on Quotidian Hemeral and Nocturnal Hemodialysis, Part II
Carl Kjellstrand, MD; Christopher Chan, MD; Gihad Nesrallah, MD

November 15th, 2006

Optimizing the Total Care of the Diabetic Patient with Kidney Disease - Lipids   
Molitch: What are the common lipid abnormalities in diabetics? In patients with CKD? In diabetics with CKD? What should our LDL targets be, and what is the evidence for going below an LDL of 100 mg/dL? What are the main RCTs in the field and what do analyses of subgroups of patients with CKD in these major trials teach us? What did the 4D trial show? What about treating lipids in transplant patients? How do we use lipid-lowering drugs in CKD? (ASN Renal Week 2005).

Annual Dialysis Conference 2006
now in MP3

How to Set-Up a Successful Home HD Program
Robert S. Lockridge, Jr., MD

Why Cardiovascular Mortality Risk is Lower on Quotidian HD
Christopher Chan, MD

Nocturnal HD Corrects the Unphysiology of Intermittent HD
Robert M. Lindsay, MD

Solute Kinetics 101, or Understanding Kinetic Modeling for the Non-Mathematician
George O. Ting, MD

How We Can Stop Worrying About Hyperphosphatemia, Phosphate Binders and Dietary Phosphate Restrictions
Carl Kjellstrand, MD, PhD

New K/DOQI PD Guidelines Are the Standard
John Burkart, MD

Deterioration of Clinical Status Only Detects Inadequacy and Does Not Prevent It
Salim Mujais, MD

The Clinical Status of PD Patients is a Good Guide to Adequacy
Joanne Bargman, MD

Has Early Initiation of Dialysis Clearly Been Shown to Be Important?
Rajnish Mehrotra, MD

Flaws in K/DOQI PD Guidelines
Peter G. Blake, MB

Thomas A. Depner, MD

Hemodialysis Access
Anatole Besarab, MD

Peritoneal Dialysis
John Burkart, MD

Research Recommendations
Michael Rocco, MD

November 3rd, 2006

Permissive Hypercapnia in Acute Pulmonary Disorders: Morbidity and Mortality and Treating the Respiratory Acidosis   
Lanken: What do we mean by permissive hypercapnia? What is the physiology behind its use? What do the animal studies show? By what mechanisms might it protect the lungs? How is permissive hypercapnia used in management of status asthmaticus? How is it used to treat ARDS? What did the randomized trials of this method of ventilation show? What are the renal implications of targeting serum bicarbonate in such patients? (ASN Renal Week 2005 Clinical Nephrology Conference)


Lecture Free
Free CE


Anemia Management in CKD: Improving Iron Management   
John Reed, MD; Betsy Copeland, BSN, MSN, CFNP.
(ANNA National Symposium, Nashville, TN, April 2006.)
Reed: What is an evidence-based approach to iron therapy in non-dialysis CKD patients? What do the randomized controlled trials show when comparing oral with IV iron in non-dialysis CKD? What is the prevalence of anemia in stage 2 through 4 CKD? What factors predict a response to oral or to IV iron treatment? What was our experience in setting up and managing a CKD clinic? Copeland: What are the obstacles to success in treating iron deficiency in non-dialysis CKD? How did we do it? What helped in arranging timely referral? How did we find the time to give IV iron in our daily practice? How do the various injection schedules for IV iron impact ease of treatment, cost, and time management? What is our protocol for doing this?

Annual Dialysis Conference 2006
now in MP3

Coagulation Cascade
David Green, MD

Measures to Optimize Heparin Anticoagulation for HD
Andrew Davenport, MD, FRCPC

Heparin-Induced Thrombocytopenia
Karl-Georg Fischer, MD

Current Standards for Peritonitis and Exit-Site Infection Rates
Beth Piraino, MD

The Status of Drug Resistance in Organisms Commonly Causing PD Peritonitis
William Salzer, MD

Exit-Site Prophylaxis Has Clearly Been Justified and Should Be Standard Practice
Beth Piraino, MD

Exit-Site Prophylaxis Has Not Been Proven Beneficial
William Salzer, MD

Statistical Methods in Dialysis
Edward Vonesh, PhD

PD Growth ~ Asia and Australia
Wai Kei Lo, MBBS

PD Growth ~ North and South America
Ricardo Correa-Rotter, MD

PD Growth ~ Europe
Raymond T. Krediet, MD, PhD

Different Catheters
Stephen R. Ash, MD

Insertion Techniques
W. Kirt Nichols, MD

Short and Long-Term Catheter Complications
Adam Whaley-Connell, DO

Reimbursement Issues in Nephrology
Richard Amerling, MD

Fellow Case Presentations

October 21st, 2006

Preservation of residual renal function in hemodialysis patients   
What are the potential benefits of Kr (residual renal function) beyond volume control and solute excretion? What's the best way to measure Kr. To what extent are comparisons of Kr in HD vs. PD confounded by informative censoring bias? What animal work suggests that PD may have a preservative effect on Kr? How does Kr impact mortality in hemodialysis patients? Nutritional status? What are the factors associated with preservation of Kr in HD? Is membrane type and ultrapure dialysis solution use a factor? Is furosemide administration useful? What drugs are associated with Kr preservation? Which drugs may have a harmful effect? (ASN Renal Week 2005 Clinical Nephrology Conference).


(Article Free, $CE)
C-Reactive Protein and Anemia: Implications for Patients on Dialysis
(Vol 33/No. 5. Expires 10/20/2008)
Randee Breiterman-White, MSN, RN, CNN
1.4 hr

Perceptions of Incorporating Spirituality into Their Care:A Phenomenological Study of Female Patients on Hemodialysis
(Vol 33/No. 5. Expires 10/20/2008)
Ruth A. Tanyi, MSN, RN, APRN-BC, FNP-C; Joan Stehle Werner, DNS, RN, BCETS,FAAETS; Ann C. Gentry Recine, BSN, RN, SFO; Rita A. Sperstad, MSN, RN
1.4 hr

The Controversy Over Sodium Modeling: Should We Use It or Not?
(Vol 33/No. 5. Expires 10/20/2008)
Michael R. Henning, BSN, RN
1.4 hr

The Challenges of Using Serum Ferritin to Guide IV Iron Treatment Practices in Patients on Hemodialysis With Anemia
(Vol 33/No. 5. Expires 10/20/2008)
Andrea Easom, MA, MNSc, APN, BC, CNN
1.4 hr

Free lecture; CE requires payment to ANNA.

Annual Dialysis Conference 2006
now in MP3

History of Animal Models in PD
Andrzej Breborowicz, MD

Benefits of a Standard Animal Model
Peter Margetts, MD

Which Animal Species and Strain is Best?
Michael Flessner, MD, PhD

PD Access in Animals
Harold Moore, MA

Normal Animal Laboratory Values
Andrzej Breborowicz, MD

Long-Term Function and Structural Changes in the Peritoneum
Michael Flessner, MD

Clinical Characteristics and Unique Features, Including Blood Pressure Changes in Long-Term PD Patients
Dimitrios Oreopoulos, MD

Metabolic Problems in PD Patients
Frederic Finkelstein, MD

Middle Molecules -Are They Important in PD Patients?
James F. Winchester, MD

Nutrition Issues in PD Patients
Roberto Pecoits-Filho, MD, PhD

Non-Infectious Complications of PD
Joanne Bargman, MD

Peritonitis and Exit Site Infection
William Salzer, MD

Ultrafiltration Failure - Diagnosis
Dana Negoi, MD

Management Including Role of Icodextrin
Salim Mujais, MD

Challenging PD Patients (Including Patients with Stomas, Post-AAA Repair, PKD, Multiple Abdominal Surgeries, Post Cardiac Surgery)
Chaim Charytan, MD

Cardiovascular Issues in PD Patients: Challenges and Newer Insights
Kevin C. Dellsperger, MD, PhD

October 3rd, 2006








ASDIN 2006 Annual Scientific Meeting (Part 3)   
Ash: Tunneled Dialysis Catheters: Types and Insertion Techniques. Urbanes: Hemodialysis Cathereters: Management of infectious complications. Yu: Tunneled Hemodialysis Catheter Dysfunction. Falk: Alternative Central Venous Access: Lessons Learned. Schon: Fibrin Sheaths. Pflederer: Basilic Transposition Fistulae or Arteriovenous Grafts. Mishler: Training Nephrologists for Access Creation. Beathard: Coding issues.
(Slide/audio and lecture handouts; no transcripts). Free for ASDIN members.


(Article Free, $CE)


A Balanced Approach to Anemia Therapy: IV Iron and EPO.  
(Andrea Easom, MA, MNSC, APRN, BC, CNN, and Deborah Bowe, RN, CNN. ANNA National Symposium, Nashville, TN, April, 2006.
Easom: What are the main markers of iron status and how should they be interpreted in patients with inflammation? What are average iron losses per year? What are average iron doses? How can we diagnose functional iron deficiency? Inflammatory iron block? Bowe: How did our facility utilize a CQI approach to develop and implement an IV iron protocol? How did we put this plan into action? What impact did this have on our serum ferritin levels, hemoglobin values, and use of EPO?
Free lecture, free ANNA CE.

Annual Dialysis Conference 2006
now in MP3


Hypertension on HD: Is There a Phenomenon of Reverse Epidemiology in the HD Population?
Kamyar Kalanter-Zadeh, MD, PhD

Management of Hypertension on HD
Garry Reams, MD

Does PD Control Blood Pressure More Effectively in ESRD?
Madhukar Misra, MD

A Practical Approach to Management of Intradialytic Hypotension
Richard A. Sherman, MD

Blood Pressure Control by Gentle Ultrafiltration in Long HD
Bernard Charra, MD


CV Disease Link to Renal Osteodystrophy
Gerard M. London, MD

Which Vitamin D Analogues Are Best for Patients?
Stuart Sprague, DO

Achieving Neutral Ca/P Balance:The Roles of Dialysis, Diet, Binders and Vitamin D
Daniel W. Coyne, MD

What Are the Experiences with Calcium Receptor Agonists?
William Goodman, MD

PTH, Phosphate, Calcium, and Vitamin D: Relative Impact on Mortality
Myles Wolf, MD

September 21st, 2006






ASDIN 2006 Annual Scientific Meeting (Part 2)   
Nassar: Cephalic Vein Arch Stenosis (Lessons Learned). Falk: Arterial Steal Syndrome: Lessons Learned. Crabtree: Peritoneal Dialysis Procedures: A Surgical Approach. Ash: Peritoneal Dialysis Catheter Overview and Placement Techniques. Beathard: The Future of Dialysis Vascular Access. Hamburger: Codes and Payment. (Slide/audio and lecture handouts; no transcripts). Free for ASDIN members.

Annual Dialysis Conference 2006
now in MP3

Ramesh Khanna, MD, Raymond Krediet, MD, Lynda Szczech, MD

Solute Removal
Peter G. Blake, MB, FRCPC

Peritoneal Membrane Structure and Barriers to Transport
Peter Margetts, MD

Physiology of Ultrafiltration
Michael Flessner, MD, PhD

Peritoneal Dialysis: Present Status and Future
Dimitrios Oreopoulos, MD, PhD

Comparisons of APD and CAPD (Including Clearances, Ultrafiltration, Kinetics, Infection Rates,and Outcomes)
Dana Negoi, MD

CAPD and APD Prescription Writing (Including Adequacy and Ultrafltration, Last Bag Options)
Dimitrios Oreopoulos, MD

Summary of Clinical Use of and Experience with Neutral pH Solutions
José Diaz-Buxo, MD

Update on Solutions with Membrane Protective Agents
José Diaz-Buxo, MD

The Use of Icodextrin and Amino Acid Solutions
Salim Mujais, MD

What New Solutions Are on the Horizon?
Andrzej Breborowicz, MD

September 3rd, 2006






ASDIN 2006 Annual Scientific Meeting (Part 1)   
(David Namazy, MD; Theodore Saad, MD; Gerald Beathard, MD; George Nassar, MD; Arif Asif, MD; Deborah Brouwer MD. ASDIN 2nd Annual Scientific Meeting, San Antonio, TX. April, 2006.)
Namazy: Percutaneous Balloon Angioplasty - Primer on Tools and Techniques. Saad: Venous Stents for Hemodialysis Vascular Access: "Design Matters". Beathard: Beyond Fistula First. Nassar: Early AV Fistula Failure. Asif: Secondary Arteriovenous Fistula. Brouwer: Progress in Cannulation. (Slide/audio and lecture handouts; no transcripts). Free for ASDIN members.

Renal Week/PGE 2005
now in MP3

Lessons learned from Katrina
Hamm L., Kinney R., Philliber P., Lansing L., Clemons G.

Basic Science Evening Symposium (II)
Diamond S.

Basic Science Evening Symposium
Chien S.

The Future of Medicare Value-Based Purchasing
Tooker J., Augustine B.


(Article Free,
Paid$ CE)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Self-Care Management in Adults Undergoing Hemodialysis
(Vol 33/No. 4. Expires 08/31/2008)
Cleo J. Richard MSN, RN
1.5 hr

Patients' Perceptions Concerning Choice Among Renal Replacement Therapies: A Pilot Study
(Vol 33/No. 4. Expires 08/31/2008)
Kandace J. Landreneau, PhD, RN, CCTC
1.4 hr

Hemodialysis Special Interest Group Networking Session: Fluid Management: Moving and Removing Fluid During Hemodialysis
(Vol 33/No. 4. Expires 08/31/2008)
Diana Hlebovy, BSN, RN, CHN, CNN
1.4 hr

Adjusting IV Iron and EPO Doses in Patients on Hemodialysis Prior to Surgery: Can We Protect Our Patients From Iron-Deficiency Anemia?
(Vol 33/No. 4. Expires 08/31/2008)
Kim Deaver, BSN, RN, CNN
1.5 hr

The KDOQI Clinical Practice Guidelines And Clinical Practice Recommendations for Treating Anemia in Patients With Chronic Kidney Disease: Implications for Nurses
(Vol 33/No. 4. Expires 08/31/2008)
Patricia McCarley, MSN, RN, ACNP, CNN

August 12th, 2006








Nephrology Practice in the Information Age (Part 2)   
(Susan Price; Lori LeBlanc; Michael Somermeyer, MD; Franklin Maddux, MD; Victor Villagra, MD; Wilson Wang, MD, MPH; Domenic Ruscio, Jennifer Shevchek, Robert Blaser, MD. RPA Annual Meeting, Baltimore, MD; March, 2006 )
Price, LeBlanc: Overall practice performance. Somermeyer: CKD Outcomes. Maddux: Dialysis Outcomes - Real Time Applications of Information Technology. Villagra: John Dickmeyer Lecture: Integrating Disease Management into Nephrology Care. Wang, Ruscio, Shevcheck: Influencing Lawmakers on Capitol Hill. Blaser: The RPA's advocacy agenda.
(Slide/audio and lecture handouts; no transcripts). Free for RPA members.

Renal Week/PGE 2005
now in MP3

The Role of Podocytes in Proteinuria and Progressive Renal Disease
Kriz W., Salant D.

The Pathophysiology of Progressive Renal Disease and Hypertension: Importance of Gender and Ethnicity
August P., Maric C., Thomas M., Lewis J.

Tamm-Horsfall Protein in Health and Disease
Serafini-Cessi F., Wu X., Lens X.

Recent Advances in Regulation of Calcium, Magnesium and Phosphate Homeostasis and Metabolism
Murer H., Konrad M., Huang C., Weinman E.

Pathogenic Mechanisms of "Ischemic Nephropathy"
Lerman L., Navar L., Wilcox C., Juillard L.

Osmoregulation: Osmotically Induced Damage and Cellular Responses
Wood J., Burg M., Bolen D., Lamitina S.

New Insights into the Molecular Pathogenesis of Human Renal Malformations
Piscione T., Woolf A., Li X., Goodyer P.

New Insights in IgA Nephropathy
Haas M., Monteiro R., Feehally J., Hsu S.


(Article Free,
Paid$ CE)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Infection and Inflammation in Patients on Dialysis: An Underlying Contributor to Anemia and Epoetin alfa Hyporesponse
(Vol 33/No. 3. Expires 06/30/2008)
Randee Breiterman-White, MSN, RN, CNN
1.0 hr

Human Immunodeficiency Virus-1 Associated Nephropathy (HIVAN): Epidemiology, Pathogenesis, Histology, Diagnosis, and Medical Management
(Vol 33/No. 3. Expires 06/30/2008)
Michelle L. Lochner, MSN, RN, FNP, CNN; Andrea Wolf, BSN, RN
2.3 hr

Quality of Life: Subjective Descriptions of Challenges to Patients With End Stage Renal Disease
(Vol 33/No. 3. Expires 06/30/2008)
Safa'a Al-Arabi, PhD, MSN, MPH, RN
2.2 hr

The Buttonhole Technique for Arteriovenous Fistula Cannulation
(Vol 33/No. 3. Expires 06/30/2008)
Lynda K. Ball, BS, BSN, RN, CNN
1.4 hr

Use of Electronic Self-Monitoring for Food and Fluid Intake: A Pilot Study
(Vol 33/No. 3. Expires 06/30/2008)
Shannon Dowell, MSN, RN, CNS, CCTN ;Janet Welch, DNS, RN, CNS
1.3 hr

July 28th, 2006



Practical Considerations for the Management of Anemia in Dialysis Patients   
(RPA Satellite Symposium. Baltimore, MD. March 2006.)
Pereira: Epidemiology, past failure, and future opportunities. Anemia begins early in CKD, its prevalence is high, anemia predicts progression and vascular disease, and is a risk factor for death and increased hospitalizations and costs. Transplant patients and patients starting dialysis are particulary at risk. Wish: What are the economics of anemia management? What are the costs of therapy? How is therapy reimbursed? Can economic benefits of ESA therapy be quantified? What is the cost ratio of darbepoetin to epoetin alfa? How are ESAs reimbursed in CKD? Why is it all about payer mix? How can one avoid losing money prescribing ESA treatment? Aronoff: How does epoetin alfa work? What is CERA and how is it different? What are the half-lives of various ESAs and how may this impact therapy and cost? What is Hematide and how does it work? What are prolyl hydroxylase inhibitors and how do they affect anemia? What are initial results with FG-2216? How can ESA dosing be individualized using a neural net approach?







Nephrology Practice in the Information Age (Part 1)   
(Robert Provenzano, MD; Janet M. Marchibroda; William E. Haley, MD; Carolyn Hartley; David Kibbe, MD; Michael Germain, MD; Steven Fadem, MD. RPA Annual Meeting. Baltimore, MD. March 2006.)
Provenzano: Year in review. Marchibroda: Using information technology in medical practice. Haley: Implementation of the RPA CKD Toolkit and its Potential Impact on P4R and P4P. Hartley: How to Implement Information Technology in Your Practice. Kibbe, Germain, Fadem: How to Invest IT Without Going Broke. (Slide/audio and lecture handouts; no transcripts). Free for RPA members.

Renal Week/PGE 2005
now in MP3

Inflammation, Dyslipidemia and the Kidney
Massy Z., Tonelli M., Danovitch G., Kasiske B., Landray M.

Hypoxia and Renal Cancer
Kaelin W., Simon C.

High Throughput Tools for Identification of Therapeutic Targets
MacRae C.

Antibody Mediated Responses in Allo and Autoimmunity
Wasowska B.

Advances in Hemodialysis Vascular Access
Roy-Chaudhury P., Salvatore M., Cheung A.

Scribner Award (Bennett)
State-of-the-Art Lecture: Tipping the Immune Balance Towards Tolerance (Strom)

Bennett W., Strom T.

Refractory Hypertension: Pathogenesis, Diagnosis and Therapy
Townsend R., Norris K., Sica D.

The Spectrum of Sensitization Before and After Transplantation: Management Issues
Tinckam K., Akalin E., Watschinger B., Jordan S.


(Article Free, Free CE)

Evidence-based Anemia Management  
(Patricia McCarley, MSN, RN, ACNP, CNN. ANNA National Symposium; Nashville, TN. April, 2006).
How do ESAs work, and what factors affect how well they work? What do we measure to asssess degree of iron stores? How can we separate out absolute iron deficiency from functional iron deficiency, from reticulo-endothelial blockade? What treatment algorithms can we use to prevent sub-11 Hb values? How far ahead and how often should the ESA dose be changed? What are the new CMS reimbursement rules, and how can we monitor Hb to maximize patient benefits under the new guidelines? What are the 2006 K/DOQI anemia guidelines? What do they say about ESA use, testing for anemia and iron deficiency, and upper limits of Hb and ferritin? (Free lecture, free ANNA CE).

July 12th, 2006

Literature Review: Non-Potassium Fluid-Electrolyte and Acid-Base Disorders   
(ASN Renal Week Clinical Nephrology Conference November, 2005, Philadelphia, PA)
Why and when do marathon runners become hyponatremic? How much should they drink? What should then drink? Are NSAIDs a risk factor? What is the nephrogenic syndrome of inappropriate diuresis, and what is its molecular and genetic basis? How does sildenafil act on aquaporins to increase water transport in the kidney? How does "ecstasy" cause hyponatremia? How can we use CRRT to safely treat extreme hypernatremia? How to thiazolidinediones cause edema? What is pyroglutamic acidosis? How can medication containing propylene glycol cause acidosis? How does acidosis affect protein synthesis in the kidney? What is hensin and how can it explain cyclosporine caused metabolic acidosis? How to topamax, linezolid, and propofol cause acidosis? How does bicarbonate ingestion boost athletic performance?

Renal Week/PGE 2005
now in MP3

Renal Biopsy: Clinical Correlations
Walker P., Smith K., Chander P., Barisoni L.

Newer Approaches to Diabetic Kidney Disease (DKD)
Hollenberg N., Lewis J., Pavlakis M.

Genetic Renal Disease Emerging in Adulthood: Diagnosis and Management
Avner E., Bleyer A., Goodyer P., Gahl W.

The Pathway to Approval of Novel Agents for Renal Diseases
Greene T., Throckmorton D., Lewis E.

The High Risk Transplant Patient
Kiberd B., Wali R., Adey D., Chapman J., Chandraker A.

Stones and Bones
Coe F., Kramer H., Thakker R.

Role of Ion Transporters in Regulation of Protein Trafficking
Gluck S., Yasui M., Guggino W., Muallem S.

Regulatory T Cells
Wood K., Salama A., Lechler R.

June 26th, 2006

Obesity in the Peritoneal Dialysis Population: Impact on Modality Selection and Outcomes   
(ASN Renal Week Clinical Nephrology Conference November, 2005, Philadelphia, PA)
To what extent is BMI increasing in the general population vs. CKD? Is this occurring in all age groups and races? How does elevated BMI affect mortality in hemodialysis patients? In diabetics vs. nondiabetics? Does BMI predict survival in PD? In not, why not? How does BMI related to technique survival and likelihood of transplantation? Does PD increase the risk of diabetes? If so, over what time period and how does this differ among different age groups?



Resistant Hypertension: Reducing Cardiovascular Events   
(ASN Renal Week Official Symposium. November, 2005, Philadelphia, PA)
White: During introductory remarks, two cases of resistant hypertension are presented to set the stage. A young woman who works in a hospital on 3 drugs with BP 160/100, and an elderly retiree who finds that his AM BP is quite elevated on home monitoring. Calhoun: What is the prevalence of primarly aldosteronism in hypertensives, and how does this depend on the resistance of hypertension to treatment? What percent of hypertension is low-renin. To what degree does resistant hypertension respond to aldosterone blockers, and does this depend on aldosterone excretion rates? How are high-aldosterone hypertensives different from those with normal aldo levels in terms of endothelial dilation, LVH, and other measures? How can aldosterone blockade as well as salt intake modify endothelial vasodilatory capacity and LVH? White: In resistant hypertension, what other drugs can we use? How do CCB/ACE combos compare to BB/D? What dose of diuretic should be added to an ACE/ARB regimen? Is ARB half-life important? What are new drugs on the horizon? Cosio: What should target LDL-C (LDL cholesterol) levels be for CKD patients? How do CV risk factors cluster in CKD patients? Which dyslipidemias are associated with increased risk? How can one treat low HDL-cholesterol? What did the ALERT and 4-D trials show? How do we explain the negative results of the 4-D trial?

Renal Week/PGE 2005
now in MP3

Polycystins: From Cell Signaling to Gene Regulation
Chauvet V., Tsiokas L., Germino G.

Overview of Modern Bioinformatic Tools and Approaches
Butte A., Abecasis G., Jacob H., Gerstein M.

Novel Pathways for Prevention of Diabetes and Obesity-Related Renal and Vascular Disease
Cooper M., Danesh F.

Mechanisms of Systemic Vasculitis
Jennette J., Savage C., Jayne D.

Macrophages and Renal Disease
Cosgrove D.

How Does the Cytoskeleton Inside the Closet Modulate Our Cellular Functions?
Bamburg J., Donaldson J., Titus M.

FXYD Proteins in the Kidney
Karlish S., Maunsbach A., Arystarkhova E., Capasso J.

Epithelial to Mesenchymal Transition
Hay E.

Endothelial Dysfunction in CKD
Ballermann B., Leopold J., Goligorsky M.

Childhood Hypertension: The View in 2005
Flynn J., Bertram J., Portman R.

Angiogenesis in Health and Disease
Fisher S., Maeshima Y.

Improving Clinical Outcomes for Hemodialysis Patients in the International Dialysis Outcomes and Practice Pattern Studies (DOPPS)
Lameire N., Locatelli F., Marshall M., Mendelssohn D., Wolfe R.

June 9th, 2006

The Role of Glycemic Control and How Best to Achieve it   
(ASN Renal Week Clinical Nephrology Conference November, 2005, Philadelphia, PA)
To what extent does HbA1c predict adverse events in diabetics? In non-diabetics? How low must one go to avoid the increased CV risk? Is <7.0% low enough? What did follow-up from the DCCT/EDIC trials show? What is the benefit of multiple risk factor reduction (Steno-2 Trial)? What is the modern approach to glucose control, including use of metformin (in non-CKD), alpha-glucosidase inhibitors, incretins, secretagogues, and thiazolidinediones? What are practical points regarding use of PPAR-gamma agonists, exenatide? What are the benefits of the thiazolidinediones in terms of lipids, prevention of restenosis, and reduction of albuminuria?

Renal Week/PGE 2005
now in MP3

The Latest KDOQI Updates
Besarab A., Rocco M., Depner T.

Evidence for a New Treatment Paradigm in the Management of Secondary Hyperparathyroidism in CKD Stages 3 and 4
Andress D., Coyne D.

Controversies in Managing Hyperphosphatemia in CKD and ESRD
Young E., Rosas S., Goldfarb S.

Non-Amyloid Dysproteinemias and the Kidney
Ronco P., Korbet S., Madore F.

Nephrology Quiz & Questionnaire
Halperin M., Danovitch G., Falk R., Bargman J.

Issues in Lupus Nephritis
Rifkin I., Levine J., Austin H., Appel G.

Clinical Issues in Hemodialysis (HD)
Cheung A., Shoji T., Lameire N., Spergel L.

Advances in the Treatment of Renal Osteodystrophy
Goodman W., Sprague S.

May 23rd, 2006



Transplantation: Key Issues for the General Nephrologist   
(ASN Renal Week Official Symposium. November, 2005, Philadelphia, PA)
Rigatto: How does cardiovascular disease manifest in transplant patients and how should we manage it? What are the BP targets, lipid, and HbA1c goals, and indications for beta-blockers, ASA, and statins? What did the ALERT trial show re fluvastatin? What is the impact of pre-emptive transplantation on CVD? Murphy: What is the epidemiology of chronic allograft nephropathy? What are the management options in terms of prevention protocols? With calcineurin withdrawal protocols, what are results using MMF or alternatively, sirolimus? What are the data using belatacept? Campath (alemtuzumab)? Mannon: What are our choices for maintenance immunosuppression agents? Induction agents? What are some of the standard regimens? What are mechanisms of actions of the major drug classes? What are common drug interactions? Side effects? Toxicities? What approaches can we use to achieve calcineurin-free immunosuppression? Steroid-free immunosuppresssion? What are the newer agents on the horizon? (2.0 CME credits)

Renal Week/PGE 2005
now in MP3

Homer W. Smith Award and Address / Diet and Optimal Health: A Progress Report
Boron W., Willett W.

Management Issues in Systemic Lupus Erythematosus
Austin H., Parfrey P., Cohen D.

Transplantation: Key Issues for the General Nephrologist
Rigatto C., Mannon R.

Strategies for Reducing Parathyroid Hyperplasia, Fractures and the Need for Parathyroidectomy in Renal Disease
Fukagawa M., Cunningham J.

Resistant Hypertension: Reducing Cardiovascular Events
White W., Calhoun D., Cosio F.

New Strategies for the Prevention and Treatment of Staphylococcus aureas Infections in Hemodialysis Patients
Salzer W., Engemann J.

Vascular Access Management
DeOreo P., Urbanes A., Nguyen V., Rasmussen R.

Renal Amyloidosis: Pathogenesis, Diagnosis, and Therapy
Benson M., Herrera G., Seldin D.

Managing the Transplant Patient: What the General Nephrologist Needs to Know
Helderman J., Blumberg E., Kasiske B., Abbott K.

Literature Review : The Year in Nephrology: Fluid-Electrolytes & ICU Nephrology
Palmer B., Palevsky P.

Clinical Issues in Peritoneal Dialysis
Piraino B., Davies S., McIntyre C., Collins A.

Sodium Co-Transporter Protein Families: Molecular Biology and Regulation
Romero M., Ellison D.

May 8th, 2006




Post-Transplant Infections: Updating the General Nephrologist   
(ASN Renal Week Official Symposium. November, 2005, Philadelphia, PA)
Rubin: What are the factors that determine infection post-transplantation? What infections are seen initially, then during months 1-6, then after 6 months? What are key steps in the pathogenesis of CMV disease? Which immunosuppressants can reactivate CMV? Which ones can help it grow once reactivated? What approach should we take to antimicrobial therapy use? Pescovitz: What are the primary and secondary effects of CMV infection? How is CMV associated with rejection rate and graft survival, and how can these be altered by use of antiviral therapy? What are effects of antiviral therapy on superinfections, on cardiac complications, post-transplant diabetes mellitus? What are CMV prophylactic and therapeutic options, and which drugs can we use and how do they differ? Ramos: Who gets polyoma virus; How often does it affect the allograft; When it does, what are its consequences? How do we separate latent infection from low level viral replication or high level replication with tissue destruction? How do we diagnose polyomavirus nephritis? What is a useful treatment algorithm? (1.5 CME credits)

Renal Week/PGE 2005
now in MP3

Progression and Treatment of Fibrosis
Bissell M.

Obesity and the Kidney
Lord G., Scherer P., Fliser D.

Novel Technologies for Acute Renal Failure Therapeutic Discovery
Mehta R., Molitoris B., Portilla D.

New Immunosuppressive Agents in Renal Transplantation
Steinberg S., Grinyo J., Knechtle S.

New Developments in the Pathogenesis and Treatment of Disorders of Water Balance
Agre P., Ishikawa S., Martin P., Verbalis J.

Integrin and Cell Adhesion
Ginsburg M., Chapman H., Dedhar S.

How Do Perturbations in Lipids Modulate Renal Function?
Alpers C., Barry N.

Collapsing Glomerulopathy - A Distinct Pathogenic Entity
Barisoni L., Kopp J., Nelson P.

Co-Stimulatory Molecules in Kidney Diseases
Sharpe A., Wuthrich R., Khoury S., Guleria I.

Cilia Biogenesis and Signal Transduction
Dutcher S., Margolis B., Doxsey S., Quarmby L.

Biology of Circadian Blood Pressure Rhythms: Basic and Clinical Applications
White W., Schwartz G., Chan C.

Atherosclerosis and Vascular Calcification in CKD
Hruska K., Vanholder R., Himmelfarb J.


(Article Free, $CE)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

Erythropoietin Claims Monitoring Policy: Implications for Clinical Practice
(Vol 33/No. 2. Expires 04/20/2008)
Tony Messana
1.4 hr

Illness Representations in Patients with Chronic Kidney Disease on Maintenance Hemodialysis
(Vol 33/No. 2. Expires 04/20/2008)
Christopher Fowler, MSN, RN, CS, ACNP; Linda S. Baas, PhD, RN, CS, ACNP
2.1 hr

Assessing Advance Care Planning Readiness in Individuals with Kidney Failure
(Vol 33/No. 2. Expires 04/20/2008)
Amy O. Calvin, PhD, RN; Lillian R. Eriksen, DSN, RN
1.4 hr

April 23rd, 2006




Medical Crossfire: An Expert Panel Debates Key Clinical Issues in Mineral Metabolism and Mortality in CKD   
(ASN Renal Week Official Symposium. November, 2005, Philadelphia, PA)
This is a bit of a novel format. First Drs. Coyne, Moe, and Martin each give a very brief overview of mineral metabolism in CKD, and then they launch into an hour discussion of vascular calcification, control of serum phosphorus, and audience questions, using the Medical Crossfire™ format. Coyne: What are the associations between Ca, Pi, their product, and PTH vs. mortality in ESRD and CKD? How is this modified by active vitamin D treatment? What is Ca absorption with the various Ca-containing binders? Moe: What are traditional and non-traditional risk factors controlling vascular calcification? How can calcium load and vitamin D affect vascular calcification? Martin: As renal function falls, how do Ca, Pi, and PTH change? How can we better understand Pi balance in CKD patients? What are the potential pitfalls and advantages of the various classes of Pi binders? Finally, as mentioned initially, the main thrust of this program is in the discussion sections, which are presented in both video and audio formats.

Renal Week/PGE 2005
now in MP3

Race, Gender and Economic Status: Do They Account for Disparities in Health Care Delivery?
Satel S., Zuvekas S., Gaston R.

ClinicoPathologic Conference
Appel G., Nast C.

Post-Transplant Infections: Updating the General Nephrologist
Rubin R., Pescovitz M., Ramos E.

Anemia Management in Renal Disease: "Getting it All Together"
Collins A., Macdougall I.

Active Vitamin D Therapeutic Options: Links to Cardiovascular Outcomes in the Management of CKD
Wolf M., Llach F.

Optimizing the "Total" Care of the Diabetic with Kidney Disease
McGill J., Kaplan L., Molitch M., Williams M.

Long-Term Survival in CKD: The Obstacles
Kimmel P., Patel S., Germain M., Moss A.

Highlights from the 2005 American Transplant Congress: Renal Transplantation
Gallon L., Vanrenterghem Y., Mannon R.

Genetic Hypertension and the Cortical Collecting Duct (CCD): What Every Nephrologist Must Know!
Ferrari P., Luft F., Geller D., Auchus R.

Basic Science for Clinical Nephrologists - Mechanisms of Injury in Glomerulonephritis: A Review and Update
Julian B., VanDerWoude F., Botto M.

State-of-the-Art Lectures
Feldmann M.

Systemic and Renal AA Amyloidosis: Early Diagnosis and Treatment for a Deadly Disease
Mikhael J., Picken M., Lachmann H.

RRI 2006

Dry Weight - Neither More, Nor Less: Online Assessment of ECV During Hemodialysis
Martin Kuhlmann, MD - Universitaetskliniken des Saarlandes; Homburg, Germany

Dry Weight Online Assessment of Rebound
Roger Greenwood, MD - Lister Hospital; Stevenage, United Kingdom

The Significance of Residual Renal Function - Is it the Pee or the Bean?
John Burkart, MD - Wake Forest University Medical Center; Winston-Salem, NC

Cardiovascular Disease Causes and Consequences of Sympathetic Hyperactivity in CKD
Peter Kotanko, MD - Renal Research Institute; New York, NY

CRITICAL ASSESSMENT A Critical Evaluation of PD as a Therapy
Norbert Lameire, MD - University Hospital Ghent; Ghent, Belgium

Ivor J. Katz, MD - Dumisani Mzamane African Institute of Kidney Disease; Soweto, South Africa

The NIH Daily and Nocturnal Dialysis Study; Full Disclosure! Q & A
Rita Suri, MD, FRCPC, FACP - University of Western Ontario; London, Canada

SPECIAL DEBATE Carnitine is Valuable in Dialysis Patients
Brian Schreiber, MD - Medical College of Wisconsin; Milwaukee, WI

SPECIAL DEBATE Carnitine is Valuable in Dialysis Patients
Garry Handelman, PhD - University of Massachusetts; Lowell, MA

New Important Technologies Oral Sorbents in Uremia: Early Results
Gerald Schulman, MD, FASN - Vanderbilt University School of Medicine; Nashville, TN

Proven Strategies to Reduce CV Mortality in HD Patients
Hannelore Hampl, MD - University of Berlin; Berlin, Germany

March 25th, 2006


Van Wyck  
Anemia in Renal Disease: Update and Case Discusion
   (ASN Renal Week Official Symposium. November, 2005, Philadelphia, PA)
Dr. Berns: We have a case of a middle-aged male with epoetin hyporesponsiveness. What are the possible causes? How do we approach such a patient? Serum ferritin is 250 and TSAT is 26%. What are average EPO doses in various countries? Is there a role for EPO adjuvants (ascorbic acid, androgens, L-carnitine)? How is iron status related to restless legs syndrome? What was the outcome of this case and how was the patient cured? Dr. Van Wyck: What do we really know about use of IV vs. oral iron in nondialysis patients or in PD patients? Do we have hard evidence that IV iron is better? If so, under what circumstances? How useful are measures of iron status in such patients? What were the latest IV iron abstracts presented at Renal Week 2005 and what do they tell us?

Renal Week/PGE 2005
now in MP3

Acid-Base Enigmas: New Observations
Oh M., Lanken P., Kraut J.

USRDS: Complications of Aging in the ESRD and CKD Populations
Eggers P., Collins A., St.Peter W., Murray A., Herzog C.

Structure and Function of Basement Membrane
Yurchenco P., Reichardt L., Hopfer H.

Stem Cells in Injury and Therapy
Jackson-Grusby L., Al-Awqati Q., Bonventre J.

Renal Outcome Measures for Clinical Research Studies
Torres V., Lee V., Grimm P.

Pathophysiologic Based Strategies for ARF
King L., Star R., Morigi M.

Nuclear Receptors and our Craving for More Sugar and Fat
Horton J., Xie W., Edwards P.

RRI 2006

Dialyzer & Machine Technologies; New Applications in Practice
Richard A Ward, MD - University of Louisville; Louisville, KY

The Importance of Water Treatment & Dialysate Composition
Nicholas A. Hoenich, PhD - University of Newcastle; Newcastle upon Tyne, United Kingdom

Prevention of Medical Errors in Dialysis: Design & Implementation Strategies
Alan S. Kliger, MD - Hospital of St. Raphael; Yale University School of Medicine New Haven, CT

How to Set up and Run a Successful PD Program
Jose A. Diaz-Buxo, MD, FACP - Fresenius Medical Care; Lexington, MA

A View of Dialysis from a Nurse Practitioner
Seth Johnson, NP - Beth Israel Medical Center; New York, NY

Understanding the Finances of a Dialysis Facility
Peter B. De Oreo, MD - Centers of Dialysis Care; Cleveland, OH

Payment for Performance
Richard Goldman, MD - Renal Medicine Associates; Albuquerque, NM

Implications for Survey and Certification of Dialysis Facilities.
Composite Rate Medicare Modernization Act (MMA)

Update: Adjusted Case Mix Demonstration Project
Barry Straube, MD - Centers for Medicare & Medicaid Services; Baltimore, MD

What is Now Expected from Medical Directors of Dialysis Units?
Robert Provenzano, MD- St . John Hospital & Medical Center; Detroit, MI

March 15th, 2006

AV Fistula: Collaborating With Your Surgeon
   (ASN Renal Week Clinical Nephrology Conference. November, 2005, Philadelphia, PA)
Dr. Nguyen, in whose program close to 90% of patients are being dialyzed using AV fistulas, details in a step by step fashion the key areas where the nephrologist needs to communicate with the vascular surgeon in order to attain this goal. Nephrologist responsibilities include obtaining more knowledge about the details of AV fistula placement, and all of the regions where fistulas can be placed, and he suggests visiting the operating room to gain a better understanding of the problems faced by surgeons. Important factors include vein preservation, early referral, and vein mapping and planning. What are minimum vein and artery diameters? What are the functional tests that one can use? What is the importance of mapping veins in patients with grafts BEFORE the grafts thrombose? What is the importance of regional vascular access centers, and when should patients be referred out of town?

Columbia University

Biopsy Conference: Uveitis and Renal Insufficiency

(Columbia University Nephrology and Pathology Faculty; March, 2006)

A Caucasian woman in her 60s was referred with renal insufficiency (serum creatinine 1.8 mg/dL, unknown baseline). Headaches x 3 months. Past medical history: 18 months prior, she was diagnosed with uveitis, treated with ocular steroids. 6 months prior, diagnosed with hypertension; BP 185/105, scleral erythema, no edama, otherwise normal. Serum creatinine 1.8 mg/dl; Urine microscopy: 14 WBC/HPF, no RBC Urine protein: 277 mg/24 hours; Renal ultrasound: normal sized kidneys C3, C4 depressed, ESR 27, serologies negative. What is the differential diagnosis? Teaching points: The TINU syndrome consists of bilateral anterior uveitis and interstitial nephritis, and is a diagnosis of exclusion. It typically affects young females. The renal disease is usually self-limiting, but uveitis may recur.
(Edited by Jai Radhakrishnan, MD). (more...)

Renal Week/PGE 2005
now in MP3

Molecular Signaling During Renal Development
Licht J.

Molecular Imaging: Visualizing Protein Functions in Real-Time
Piston D., Gratton E., Singer R.

Kidney-Heart Interactions

Pfeffer M., Ritz E., Burnett J.

Innate Immunity

Poudyal M., Kupiec-Weglinski J., Rudensky A., Kronenberg M.

How Do Molecules Cross Membranes? Understanding Transport at the Molecular Level

Jordan P., Engel A., Holmgren M., Miller C.

Fc Receptors and Their Role in Renal Disease

Ravetch J., Smith K., Kimberly R.

Aldosterone, Resistant Hypertension and Target Organ Injury

Calhoun D., Goodfriend T., Weber K., Geller D.

Managing Renal Osteodystrophy: Discussion of Interesting Cases

Sprague S., Moe S.


(Article Free, $CE)
ANNA CE (NNJ vol. 33, no. 1)
Target audience: Nurses. Article free, CE requires payment to ANNA via HDCN.

The Effectiveness of Low-Dose Maintenance IV Iron Therapy: A Dialysis Facility's Experience
(Vol 33/No. 1. Expires 02/20/2008)
Peter Juergensen, PA-C; Fredric Finkelstein, MD
1.0 hr

Morbidity and Mortality in Patients on Dialysis: The Impact of Hemoglobin Levels
(Vol 33/No. 1. Expires 02/20/2008)
Mary Brattich, RN, BSN, CNN
1.2 hr

Scleroderma: A Case Presentation
(Vol 33/No. 1. Expires 02/20/2008)
Sara Otterness, RN, CNP, CNN
1.0 hr

Amyloidosis and Its Impact on Patients With ESRD
(Vol 33/No. 1. Expires 02/20/2008)
Sandra D. Copeland, MSN, RN, BC
1.0 hr

Diabetic Nephropathy in Patients with Type 1 Diabetes Mellitus
(Vol 33/No. 1. Expires 02/20/2008)
Troy A. Russell, MSN, RN, APRN, BC, CNN
2.5 hr

(Target audience: Nurses. Article free, CE paid)

March 6th, 2006


Current Concepts in Neurohormones: Vasopressin and the Kidney
   (Robert W. Schrier, MD, and Richard H. Sterns, MD. ASN Renal Week Official Symposium. November, 2005, Philadelphia, PA)
Schrier: How are body fluid volumes regulated, and what is the pathogenesis of edema? What are hemodynamic and hormonal changes associated with vascular underfilling? How do V2 receptors fit into this scheme? What effect do V2R antagonists have in heart failure? What is the pathophysiology of sodium and water retention in heart failure? How does aldosterone antagonism affect this? What role is played by renal nerves? When does the adaptive response to underfilling become maladaptive? What role do diuretics and vasopressin antagonists play in heart failure? What is the pathophysiology of salt and water retention in cirrhosis? What causes vasodilatation in this syndrome? What role does NOS play? How are vasopressin receptors involved? Sterns: What are management options for treating hyponatremia? In acute hyponatremia in marathon runners, how quickly should we correct the serum sodium? What are the dangers of acute hyponatremia? How and why are these attenuated with chronic hyponatremia? What are safe rates of correction for chronic hyponatremia in terms of risk of osmotic demyelination syndrome? What are potential problems of using hypertonic saline? How can we treat chronic hyponatremia by increasing free water clearance? What are the potential roles of demeclocycline, urea, and vasopressin receptor blockers in such circumstances? What can we learn about vasopressin antagonists and salt and water balance from the congestive heart failure studies? What is the potential role of vasopressin antagonists in managing hyponatremia? In management of heart failure? What are potential pitfalls?

Renal Week/PGE 2005
now in MP3

Current Concepts in Neurohormones: Vasopressin and the Kidney
(also posted in slide/audio/transcript mode this week)
Schrier R., Sterns R.

Contrast Induced Nephropathy (CIN): Clinical Significance and Prevention

Palevsky P., Tumlin J.

Anemia in Renal Disease: Update and Case Discussion

(Scheduled for posting in slide/audio/transcript mode later in March)
Berns J., Van-Wyck D.

Membranoproliferative Glomerulonephritis (MPGN)

Glassock R., Walker P., Cosio F.

Highlights from the 2005 Meeting of the ERA - EDTA (European Renal Association - European Dialysis and Transplant Association)

Schlondorff D., Grunfeld J., Locatelli F., Campistol J.

Chronic Allograft Nephropathy (CAN)

Colvin R., Chapman J., Chandraker A.

Cardiovascular Risk Factors and Renal Disease

Vaziri N., Bostom A., Hsueh W

Plenary Session

Berl T., Hershko A.

February 24th, 2006

Membranoproliferative Glomerulonephritis Pathology: Update
   (Patrick D. Walker, MD. ASN Renal Week Clinical Nephrology Conference, November, 2005, Philadelphia, PA)
What is the history of MPGN and how were the various subtypes characterized and recognized? What is the light, IF, and electron microscopy of type 1 MPGN? What are the three groups of type III MPGN? What is Juvenile Acute Non-Proliferative GN (JANG)? What is new about Dense Deposit Disease (type II)? What are the subcategories of DDD and what implications does this have for treatment? Why is DDD not MPGN?

Renal Week/PGE 2005
now in MP3

Transplantation: What the General Nephrologist Must Know (Part IV)
Akalin E., Danovitch G., Hricik D., Chandraker A., Martin P., Cohen D., Thomas M.

Transplantation: What the General Nephrologist Must Know (Part III)
Heeger P., Hricik D., Danovitch G., Chapman J., Bunnapradist S., Gabardi S.

Transplantation: What the General Nephrologist Must Know (Part II)
Kasiske B., Pavlakis M., Brennan D., Josephson M., Davis C.

Transplantation: What the General Nephrologist Must Know (Part I)
Norman D., Tinckam K., Danovitch G., Chandraker A., Nast C., Davis C.


Prescribing for Patients with CKD Including Dialysis
Swan S., Bennett W., DeBroe M., D'Haese P.

Metals, the Environment, and Miscellaneous Toxins
Batuman V., Nortier J., Ritz E., DeBroe M., Lewis E., Wolfe S.

Specific Nephrotoxins
Molitoris B., Berns J., Palevsky P., Shihab F., Launay-Vacher V., Isnard-Bagnis C.

General Aspects of Nephrotoxicity and Analgesics
Perazella M., Markowitz G., Clark R., DeBroe M., Elseviers M., Henrich W.

February 15th, 2006




The Role of Iron Deficiency in Anemia Management: Key Controversies    (Jay B. Wish, MD, Richard A. Zager, MD, Kamyar Kalantar-Zadeh, MD, PhD, and Rajiv Agarwal, MD; Moderators: Jay B. Wish, M.D. and Anthony Besarab, MD. ASN Renal Week Official Symposium, November, 2005, Philadelphia, PA)
Wish: What do the standard determinants of iron status, the ferritin and TSAT tell us, and what are their limitations? What are the relative advantages of reticulocyte Hb concentration? Why is it hard for US nephrologists to use percent hypochromic red cells? How useful is soluble transferrin receptor? Hepcidin? What does SQUID imaging tell us about iron overload in ESRD patients? Kalantar-Zadeh: What does ferritin do? What factors affect serum ferritin other than iron? In the large DaVita database, how is mortality (both unadjusted and adjusted) related to various serum levels of ferritin, TSAT, and iron? How does IV iron administration affect mortality at different ferritin levels? Zager: Iron is a nephrotoxin in experimental models. What is the mechanism. How does the carbohydrate core of IV iron products impact on their pro-oxidant and por-inflammatory effects in a variety of in vitro and animal models? Agarwal: Using acute, in vivo models of IV iron administration, what effects are seen when various compounds are given to ESRD patients? What effects are seen on lipid peroxidation? Endothelial dysfunction? Malonyldialdehyde as a marker of lipid peroxidation? Do glutathione or NAC exert a protective effect? What effects do IV iron preparations have on enzymuria and proteinuria?

Renal Week/PGE 2005
now in MP3


Emerging Concepts in Cardiovascular Disease
Stenvinkel P., Moe S.

New Concepts in Renal Replacement Therapy
Vanholder R., Pierratos A., Burkart J., Cheung A., Allon M.

The Nephrologist in the Dialysis Unit
Drueke T.

How Dialysis Works
Clark W., Depner T., Ward R., Szczech L.


ICU Nephrology and Acute Renal Failure: What the Nephrologist Must Know (Part IV)
Palevsky P., Marshall M., Tolwani A., Goldstein S., Mueller B., Goldfarb D.

ICU Nephrology and Acute Renal Failure: What the Nephrologist Must Know (Part III)
Kellum J., Molitoris B., Okusa M., Gines P.

ICU Nephrology and Acute Renal Failure: What the Nephrologist Must Know (Part II)
Hollenberg S., Parrillo J., Kasner S., Bekes C.

ICU Nephrology and Acute Renal Failure: What the Nephrologist Must Know (Part I)
Fuchs B., Dellinger R., Palevsky H., Parrillo J.

February 1st, 2006


Workshop Cases - Hyponatremia and Hypernatremia. Part 2 of 2.    (Tomas Berl, MD; Stephen Gluck, MD. ASN Board Review Course. San Francisco, CA. August, 2005)
Three more cases. Case 1 (Gluck): Dialysis patient with few symptoms and a serum sodium of 185 mEq/L. Fact or factition? (OK, we must made this word up!) Case 2 (Berl): Sixteen year old girl with serum sodium of 118 who collapses at a dance party with respiratory arrest and later, seizures. How do we diagnose the cause, and how can we safely treat this young patient? Case 3: ICU patient with bacterial pneumonia with serum sodium increase from 140 to 148. What could be causing this? How do we explain his urinary osmolality of 425 and urinary sodium of 15? Then a long, very interesting question and answer session. Suggest that you print out the "small slide" version of the file for your reference to follow the Q&A.

Renal Week/PGE 2005
now in MP3

Secondary Hypertension
Gomez-Sanchez C., Dworkin L., Toto R.

Influence of Lifestyle on Hypertension, CKD, and CVD
Kramer H., Tuttle K

Treatment of Hypertension in CKD
Adler S., Toto R., Levin A., Peixoto A., Weir M

Hypertension in Special Populations
Portman R., Izzo J., Norris K., August P., Sarnak M.

Hypertension, CKD, and CVD Risks
Moe S., London G., Sarnak M.

Glomerulonephritis Update: Diagnosis and Therapy (Part IV)
Korbet S., Kupin W., Appel G., Charytan D.

Glomerulonephritis Update: Diagnosis and Therapy (Part III)
Falk R., Pusey C., Appel G.

Glomerulonephritis Update: Diagnosis and Therapy (Part II)
Rennke H., Glassock R., Appel G., Cattran D., Korbet S.

Glomerulonephritis Update: Diagnosis and Therapy (Part I)
Appel G., Rennke H., Cattran D., Falk R., Korbet S.

January 24th, 2006


Workshop Cases - Hyponatremia and Hypernatremia. Part 1 of 2.    (Tomas Berl, MD; Stephen Gluck, MD. ASN Board Review Course. San Francisco, CA. August, 2005)
Three cases. Case 1 (Berl): A young woman who developed hyponatremia while running a marathon. What are the risk factors? What can be done to prevent this? What is the treatment? Case 2 (Gluck): Hypernatremia in a patient with nasogastric suction. What are the diagnostic possibilities? What lab tests are needed to make the diagnosis? How do we compute the free water deficit and what is a good strategy for correction? Case 3 (Gluck): Hyponatremia and volume depletion in an alcoholic. How do we restore volume while preventing a rapid rise in serum sodium, in this patient who is at risk for pontine myelinolysis? (Another 3 cases from the same session next week.)

Renal Week/PGE 2005
now in MP3

Part 4. AVF creation, endovascular managment, thrombectomy, interventional coding, training and credentialing.
Pflederer T., Nassar G., Falk A., Schon D., Saad T.

Part 3. Tunneled catheters, PD catheters, Vein mapping
Hoggard J., Samaha A., Abreo K., Beathard G.

Part 2. Thrombectomy, Venous stents, Ultrasound Imaging, Catheter care, Cases
Work J., Saad T., ONeill W., Ash S., Behrend T., Gerges A.

Part 1. Vascular anatomy, Physical exam, Basic tools, Radiation safety, Pathobiology.
Miller P., Lewis J., Beathard G., Dwyer A., Roy-Chaudhury P.

Part 4. Bioethics, Practical issues, For profit pharma trials done in MD offices
Lo B., Moe S., Calfee J., Wolfe S.

Part 3. Journal club of an observational study. Decision analysis. Kt/V debate - Cohort vs. Randomized trials.
Powe N., Wolfe R., Greene T.

Part 2. Basics. RCT, Design a study comparing HD and PD, Meta-Analysis
Appel L., Kimmel P., Garg A., Goldberg R.

Part 1. Epidemiology key principles. Case-control studies. Cohort Studies.
Feldman H., Klag M., Thadhani R.


(Article Free, $CE)
ANNA CE (NNJ vol. 32, no. 6)
Effective and Safe IV Iron and Anemia Management During Home Hemodialysis: A Dialysis Facility's Experience
(Monica Utley, RN)

Developing Clinical Protocols for Nursing Practice: Improving Nephrology Care for Children and their Families
(Michele Mills, MS, RN, CPNP; Suzanne C. White, BSN, RN; David Kershaw, MD; Joseph T. Flynn, MD, MS; Patrick D. Brophy, MD; William Smoyer, MD, FAAP)

Improving AV Fistula Cannulation Skills
(Lynda K. Ball, BS, BSN, RN, CNN)
(Target audience: Nurses. Article free, CE paid)

January 12th, 2006

Workshop Cases - Non-Anion Gap Acidosis    (Edward A. Alexander, MD. ASN Board Review Course. San Francisco, CA. August, 2005)
This is a series of 5 or 6 cases, each exemplifying a frequently encountered problem in the diagnosis and treatment of anion-gap-negative acidosis. Included is a discussion of treating diabetics with CKD, some acidosis, and hyperkalemia; use of Florinef and Kayexalate; non-gap vs. gap acidosis with ketoacidosis during the treatment phase; making sure a low bicarb is, in fact, due to acidosis; confounding effect of UTI with urea-splitting organisms; types of RTA wth lupus; dilutional effects due to IV saline administration; and acid-base disorders with Sjogren syndrome and with multiple myeloma.

Renal Week/PGE 2005
now in MP3


Developing Therapeutics for Progressive Renal Disease
Martin G., Mauer M., Klein J., Throckmorton D., Hostetter T., Kopp J.
6 talks
Cell Injury and Recovery: How Do the Cell and Its Milieu Mediate Progressive Renal Disease?
Bissell M., Weber K., Schnaper H., Savill J.
4 talks
Matrix and Remodeling: What Are the Molecular Mechanisms of Fibrosis?
Abrahamson D., Ramirez F., Sakai L., Murphy-Ullrich J., Kang D., Basile D., Eddy A.
7 talks
Organ Models of Tissue Fibrosis: What Insight Can We Gain into Mechanisms?
Kopp J., Diegelmann R., Noble P., Cowper S., Ingelfinger J., Kriz W.
6 talks


(Article Free, $CE)


Anemia and Iron Management: Addressing Challenges and Generating Solutions.  
(Andrea Easom, MA, MNSC, APRN, BC, CNN, and Vaughn Folkert, MD. ANNA Fall Symposium; Kansas City, MO. September, 2005).
Easom: What are the comorbidities associated with iron-deficiency anemia? What are current K/DOQI standards of care? How are both EPO and iron important? Folkert: How do we approach challenging patient issues such as high serum ferritin? Functional iron deficiency with RE blockade? EPO hyporesponsiveness.
Free lecture, free ANNA CE.

December 24th, 2005

Hypertensive Urgencies and Emergencies: Clinical Syndromes And Therapy    (Stephen C. Textor, MD. ASN Board Review Course. San Francisco, CA. August, 2005)
How do we define hypertensive urgencies and emergencies and what is their prevalence? What are the clinical manifestations, and what are basic treatment principles? What specific drug regimens can be practically used? How would we treat a 44 year old farmer with a BP of 220/130 with gradual confusion and belligerence and a creatinine of 1.3 mg/dL? How would be approach a 48 year old woman who develops excruciating chest and back pain midway through PTRA for fibromuscular dysplasia? What are useful intravenous agents, and what are preferred drugs for selected hypertensive emergencies?

HDCN home
/about our site / subscribe to key zone / register for free zone
update email address / subscription status / forget your password?